Brigatinib 180mg

COMPOSITION:

Each film-coated tablet contains Brigatinib……………………………. 180 mg

INDICATION:

LuciBriga is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

DOSAGE AND USE:

90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciBriga during Pregnancy and Lactation.